PANASONIC-CORPORATION
16.3.2021 03:15:09 CET | Business Wire | Press release
Panasonic Corporation has begun licensing the HD-PLCTM 4*1 IP core required for the design of semiconductors with technologies and functions that comply with the IEEE 1901–2020*2 international standard. This IP core is the fourth generation of the HD-PLC series. Although conventionally HD-PLC have used power lines for transmission, this new series enables transmission through existing metal wires, such as control lines and coaxial cables as well as power lines, expanding its range of applications. This new HD-PLC technology also enables higher speeds, greater distance, and less wiring for wired communications.
By using this IP core, semiconductor and peripheral equipment manufacturers will be able to flexibly meet to a range of IoT service requirements and manufacture products that respond to these needs.
As a wide range of equipment in society becomes digitalized and connects to the IoT devices, communication technologies are becoming increasingly important. While the adoption of wireless technologies such as 5G and high-speed fiber optic internet gains pace, there are some locations in which it is difficult to access wireless communication. Here, the use of existing metal wires—in the walls and ceilings of buildings, underground facilities, and equipment—as communication mediums fulfils a vital role. This IP core is a solution that can rapidly meet to the requirements of the era of IoT, such as higher-speed networks, enhanced security, and internet protocol networks. By combining the IP core with wireless and other technologies, it can help create optimal networks in a range of environments, from living spaces to social infrastructure.
Using its experience and achievements with the HD-PLC 3 IP core, which is currently on the market, in addition to licensing of this new IP core, Panasonic will provide one-stop development support to users which will include proposals for analog front-end circuitry—key to the mounting of semiconductors. Further, as a high-speed wired communication solution, Panasonic will seek to use this technology to expand the adoption of IoT PLC, ultimately applying the technology to large-scale networks that cover living spaces, buildings, factories, smart cities, and other social infrastructure.
This IP core is first licensed to Socionext Inc. This enables the supply of higher performance semiconductors with lower energy consumption using fourth generation HD-PLC. It is expected that these will then be built-in to a range of IoT-connected devices.
Panasonic launched a dedicated website with more information about this technology. Please note that the global IEEE SA and HD-PLC Alliance*3 Webinar will be held on March 18, 2021.
Main Features
- The standard mode communication band (250 Mbps) can be doubled or quadrupled, allowing a 500 Mbps*4 communication speed in double mode or a maximum of 1 Gbps*4 in quadruple mode on coaxial cable or dedicated line.
- The standard mode communication band can be compressed on two levels (half or quarter), concentrating and extending the communication distance up to twice*5 the distance in standard mode.
- With the multi-hop function, it is possible to operate a wide area network of up to 1024 nodes.
Main Specifications
Communication
|
High-speed mode (1 Gbps, 500 Mbps) *Optional Standard mode (250 Mbps) Long-distance mode (2 x or 1.5 x the range of standard mode) |
Approved
|
IEEE 1901-2020 ITU-T G.9972 (Coexistence mechanism for different PLC systems) ITU-T G.9905 (Multi-hop) *Optional EN 50561-1:2013 (Dynamic notch and dynamic power control) |
Inquiries Regarding IP Core Licensing
IoT PLC Project Help Desk
Email: hd-plc_press@ml.jp.panasonic.com
Website: https://www.panasonic.com/global/business/hd-plc/en.html
*1: HD-PLCTM
is the name of the high-speed power line communications system proposed by Panasonic Corporation, and is a trademark or registered trademark of Panasonic Corporation in Japan and other countries. HD-PLCTM
4 is the name of the fourth-generation semiconductor IP core.
*2: Formulated by the IEEE Standards Association (a communication standards subsidiary of the Institute of Electrical and Electronics Engineers) on January 19, 2021, this is a standard for technologies with higher speeds and longer distances than those outlined in IEEE 1901-2010.
IEEE 1901-2020 - IEEE Standard for Broadband over Power Line Networks: Medium Access Control and Physical Layer Specifications: https://standards.ieee.org/standard/1901-2020.html
*3: An alliance formed on September 25, 2007, to support, promote and implement the HD-PLC system for High-Speed Power Line Communications and to ensure mutual compatibility.
Website: https://hd-plc.org/
*4: 500 Mbps and 1 Gbps are theoretical speeds at the physical layer.
*5: Maximum distance may change depending on communication environment.
About Panasonic
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 528 subsidiaries and 72 associated companies worldwide, recording consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global
.
Source: https://news.panasonic.com/global/press/data/2021/03/en210316-2/en210316-2.html
Related Links
IEEE SA and HD-PLC Alliance Webinar March 2021: Home Networking, Industrial and Building Automation through HD-PLC (High Speed Powerline Communication)
https://standards.ieee.org/events/index.html
[Press Release] Panasonic's Next-generation HD-PLC®
, BPL Communication Technology Adopted as IEEE 1901a Standard
https://news.panasonic.com/global/press/data/2019/03/en190325-4/en190325-4.html
Socionext Inc. related press release
https://www.socionext.com/en/pr/sn_pr20210309_01e.pdf
HD-PLC Alliance
https://hd-plc.org/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005858/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
